X4 Pharmaceuticals Inc Stock Price, News & Analysis

X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, approved by X4's Compensation Committee, consist of options to purchase 744,468 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.6693 per share, equal to the closing price on September 30, 2024.

The options will vest over a four-year period, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. These awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for new employees joining X4 Pharmaceuticals.

X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, granted on August 30, 2024, consist of options to purchase 230,588 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.70 per share, equal to the closing price of X4's stock on the grant date. The options will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and was approved by X4's Compensation Committee.

X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on rare immune system diseases, has announced its participation in three major investor conferences in September 2024. These include:

• Morgan Stanley 22nd Annual Global Healthcare Conference on September 4
• Wells Fargo Healthcare Conference on September 5
• Cantor Fitzgerald Global Healthcare Conference on September 17

The company will engage in fireside chats and one-on-one meetings at these events. Live webcasts for the Morgan Stanley and Cantor Fitzgerald conferences will be available on X4's website, with replays accessible afterwards. Investors interested in one-on-one meetings should contact their respective conference representatives.

X4 Pharmaceuticals (Nasdaq: XFOR) reported Q2 2024 financial results and corporate updates. Key highlights include:

1. First U.S. commercial sales of XOLREMDI™ (mavorixafor) following FDA approval in April 2024 for WHIM syndrome.
2. Positive interim data from Phase 2 trial of mavorixafor in chronic neutropenia; full results expected in November 2024.
3. Initiated global, pivotal Phase 3 trial of mavorixafor in chronic neutropenia.
4. Recognized a $105 million gain from the sale of a priority review voucher.
5. Reported net income of $90.8 million for Q2 2024, compared to a net loss of $55.7 million in Q2 2023.
6. Cash position of $169.5 million as of June 30, 2024, expected to support operations into late 2025.

X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, approved by X4's Compensation Committee, consist of options to purchase 708,236 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.8001 per share, equal to the closing price on July 31, 2024. The options will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for inducement material to new employees.

X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, has announced its plans to report second quarter 2024 financial results and provide corporate updates on August 8, 2024. The company will host a conference call and webcast at 8:30 a.m. ET on the same day.

Investors and interested parties can access the conference call by dialing 1-800-225-9448 (US) or 1-203-518-9708 (international) with the conference ID: X4PHARMA. A live webcast will also be available through the investor relations section of X4 Pharmaceuticals' website. Following the call, a webcast replay will be accessible on the company's website.

X4 Pharmaceuticals has announced positive interim data from its ongoing Phase 2 trial of mavorixafor in chronic neutropenia (CN). The study showed that 100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increases with once-daily, oral mavorixafor, either alone or with stable-dose granulocyte colony-stimulating factor (G-CSF). Participants on mavorixafor monotherapy achieved durable mean ANC levels above the lower limit of normal for CN at Months 3 and 6. The company also initiated a pivotal Phase 3 trial named 4WARD to further evaluate mavorixafor's efficacy, safety, and tolerability in CN. The 52-week, randomized, double-blind, placebo-controlled study aims to enroll 150 participants globally.

X4 Pharmaceuticals announced inducement awards for new employees, effective May 31, 2024.

The awards, under the 2019 Inducement Equity Incentive Plan, consist of options to purchase 166,353 shares of common stock at $1.01 per share.

These options have a ten-year term and vest over four years, subject to continued employment. The awards were approved by X4's Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

X4 Pharmaceuticals (Nasdaq: XFOR) will host a virtual investor event on June 27, 2024, at 8:00 AM ET to present new interim results from a Phase 2 clinical trial on mavorixafor for treating chronic neutropenia (CN).

The webcast will showcase hematological data from at least 15 participants, treated either with mavorixafor monotherapy or in combination with G-CSF. Experts will provide insights on the clinical results and the high unmet need in CN treatment.

The company plans to start a global Phase 3 trial in the current quarter to assess the efficacy, safety, and tolerability of mavorixafor in patients with various types of CN facing recurrent infections. A Q&A session will follow the presentation.